Croda International stock analysis
Want to see GB:50GP full AI Analyst Report?
Croda International (50GP) Share Price & Analysis
50GP Stock Chart & Stats
- Day’s Range
- GBX 74.75 - GBX 74.75
- 52-Week Range
- GBX 74.75 - GBX 84.00
- Previous Close
- GBX 77.00
- Volume
- N/A
- Average Volume (3M)
- 1,067
- Market Cap
- GBP 5.08B
- Enterprise Value
- GBP 4849.71T
- Total Cash (Recent Filing)
- GBP 205.30M
- Total Debt (Recent Filing)
- GBP 783.20M
- Price to Earnings (P/E)
- 65.5
- Beta
- 0.11
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- Nov 26, 2026
- Dividend Yield
- 789.30%
Bulls Say, Bears Say
Bulls Say
Differentiated Specialty Model
Croda sells differentiated ingredients that improve product performance, sustainability, and compliance rather than competing solely on commodity volume. Customer qualification and formulation integration can support recurring relationships, premium positioning, and durable revenue quality across end-markets.
Innovation-led Growth
Strong growth in Beauty Actives and Ceramides, alongside adoption of newer products, shows that innovation is translating into commercial demand. Successful launches can deepen customer relationships, expand Croda's formulation footprint, and support differentiated growth over multiple periods.
Manageable Leverage
Historically manageable leverage provides Croda with financial flexibility to fund research, capacity, and customer programs while absorbing normal end-market volatility. Although 2025 weakened the trajectory, the established balance-sheet position remains a meaningful support for medium-term resilience.
Bears Say
Weaker Earnings Power
The multi-year decline in net income indicates that Croda's bottom-line earnings power has not kept pace with its revenue recovery. Even with relatively resilient operating profit and EBITDA, continued profit pressure could constrain reinvestment, shareholder returns, and confidence in sustainable margins.
Working-capital Drag
A substantial working-capital outflow absorbs cash that could otherwise support investment, debt reduction, or distributions. Management is targeting structural savings by 2028, but the need to fund typical annual working capital and the timing of benefits may keep cash conversion uneven.
Uneven Regional Demand
Weakness in North America and pressured mass-market channels show that demand is not uniformly healthy across Croda's customer base. Growth concentrated in premium categories can improve mix, but it also leaves results more exposed to regional softness and uneven consumer-sector recovery.
50GP FAQ
What was Croda International’s price range in the past 12 months?
What is Croda International’s market cap?
When is Croda International’s upcoming earnings report date?
Is Croda International overvalued?
Does Croda International pay dividends?
What is Croda International’s EPS estimate?
How many shares outstanding does Croda International have?
Which hedge fund is a major shareholder of Croda International?
What is the TipRanks Smart Score and how is it calculated?
Croda International Stock Smart Score
Company Description
Croda International
Croda International Plc is a global enterprise specializing in the development, manufacturing, and distribution of high-performance chemicals, with its market reach spanning Europe, the Middle East, Africa, North America, Asia, and Latin America. The company's operations are strategically organized across four main divisions: Consumer Care, Life Sciences, Performance Technologies, and Industrial Chemicals. Croda's diverse product portfolio caters to numerous sectors. For agriculture, it provides solutions such as crop protection enhancers, seed treatment technologies, animal health compounds, bio-stimulants, and specialized additives for farming films. The industrial landscape benefits from its range of adhesives, lubricant components, protective coatings, polymer solutions, vehicle maintenance chemicals, and advanced additives for plastics, batteries, and catalysts, along with materials for automotive textiles and fibers. Within consumer care, Croda supplies essential ingredients for a broad spectrum of personal care applications, including skin, hair, sun, body, and baby care items, as well as components for cosmetics, deodorants, anti-perspirants, depilatories, men's grooming, and oral hygiene products. Its Life Sciences segment is a key supplier of active pharmaceutical ingredients, dietary supplements, and various health-related products. The company's expertise also extends to construction chemicals, bitumen additives, and specialized materials and polymer additives vital for electronics and devices. It offers chemistries, emulsifiers, fuel and power generation additives, and unique polymer additives designed for furniture and wood. Furthermore, Croda contributes to household, industrial, and institutional cleaning products, oleochemicals, and chemicals used in packaging, printing, and paper manufacturing, in addition to paints and coatings. A significant area of Croda's innovation lies in thermal management products and advanced bio-based phase change materials, which are critical for temperature control across varied applications, from buildings and apparel to healthcare, electronics, food refrigeration, energy storage, and automotive systems. Established in 1925, Croda International Plc maintains its headquarters in Goole, United Kingdom.
- Sector
- Basicmaterials
- Industry
- Chemicals - Specialty
- CEO
- Stephen Edward Foots
- Employees
- 5,954
- Website
- www.croda.com
- Address
- Cowick Hall, Goole, YO, DN14 9AA, GB
Croda International (50GP) Earnings & Revenues
50GP Earnings Call
Earnings Call SentimentPositive
The call conveyed a broadly positive performance: underlying sales, EPS and margins improved with clear signs of momentum in innovation-led growth (notably Beauty Actives and Pharma Ingredients), transformation savings are materializing, and strategic capacity expansions in Asia support future growth. Challenges remain—Pharma Solutions timing, Crop Protection weakness, regional/segment softness (North America mass market), working capital outflows and one-off OpEx inflation—but these are presented as manageable or phased rather than structural. Management reiterated full-year guidance (organic sales growth 3–6%) and the 3-year targets through 2028, signaling confidence in execution.
View all GB:50GP earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 14 |
| Technical Analysis | 4 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |
